Summary
Danaher Corporation reported a solid third quarter for 2019, with total sales increasing by 4.0% year-over-year, driven by a 5.0% increase in core sales. This growth was observed across both high-growth and developed markets, with notable strength in China and North America. The company's Life Sciences and Diagnostics segments were key contributors to this performance, showcasing robust core revenue growth. Despite overall revenue growth, net earnings saw a slight decrease compared to the prior year's comparable period, primarily due to tax-related charges, particularly impacting the nine-month period. The company is actively managing its capital structure and pursuing strategic initiatives, including the significant pending acquisition of GE Biopharma, for which substantial financing is being arranged. The company has made significant progress on its strategic objectives, including the successful initial public offering (IPO) of Envista, its dental business. This transaction provided approximately $2.0 billion in proceeds, which Danaher intends to use for debt redemption and dividend payments. Danaher continues to focus on innovation, cost reduction, and operational efficiency through its Danaher Business System. While facing global economic uncertainties, the company maintains a positive outlook for the remainder of 2019, emphasizing its diversified business model and ongoing investments in growth initiatives.
Financial Highlights
52 data points| Revenue | $4.38B |
| Cost of Revenue | $1.94B |
| Gross Profit | $2.44B |
| R&D Expenses | $282.60M |
| SG&A Expenses | $1.38B |
| Operating Income | $776.30M |
| Interest Expense | $24.00M |
| Net Income | $668.00M |
| EPS (Basic) | $0.90 |
| EPS (Diluted) | $0.89 |
| Shares Outstanding (Basic) | 718.80M |
| Shares Outstanding (Diluted) | 729.30M |
Key Highlights
- 1Total sales increased by 4.0% to $5,037.3 million for the third quarter of 2019 compared to the prior year, with core sales growing by 5.0%.
- 2The Life Sciences segment reported a 6.0% increase in total sales (6.5% core growth) and the Diagnostics segment saw a 6.5% increase in total sales (8.0% core growth) for the quarter.
- 3The Envista IPO was completed in September 2019, generating approximately $2.0 billion in proceeds for Danaher, intended for debt reduction and dividends.
- 4Net earnings for the third quarter were $674 million, a slight decrease from $664 million in the prior year's quarter, impacted by tax-related charges in the nine-month period.
- 5The company is actively pursuing the acquisition of GE Biopharma, with financing secured through significant debt issuances, including €6.2 billion in senior unsecured euronotes.
- 6Operating profit margins for the quarter were stable at 16.6% for the total company, though segment performance varied, with Life Sciences improving to 20.2% and Diagnostics at 16.6%.
- 7Danaher ended the quarter with a strong liquidity position, holding $14.3 billion in cash and cash equivalents.